跳转到主要内容

Danazol for treatment of women with symptoms caused by uterine fibroids

There is no evidence from randomised controlled trials demonstrating that the benefits of danazol outweigh its risks in treating uterine fibroids. Danazol is a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone which creates a high androgen and low estrogen environment, resulting in the wasting of endometrium and shrinkage of fibroids. Despite its benefits, various undesirable side effects have also been reported. These include acne, hirsutism (excess hair in females, with an adult male pattern of distribution), weight gain, irritability, musculoskeletal pain, hot flushes, and breast atrophy, which many women may not tolerate. The review found no evidence demonstrating that the benefits of danazol outweigh the risks in treating uterine fibroids.

研究背景

Uterine fibroids (myomas, fibromyomas, leiomyomas) are the most common benign tumours of the female genital tract. Danazol, a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone, has been used for many years for the treatment of women with uterine fibroids.This is an update of the review published in 2009.

研究目的

To evaluate the effectiveness and safety of danazol in women with uterine fibroids.

检索策略

We searched the Cochrane Menstrual Disorders and Subfertility Review Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 4); MEDLINE; EMBASE; Chinese Biomedical Disc; and the China National Knowledge Infrastructure for relevant trials (to December 2010). Attempts were made to identify trials from references in published studies. We also searched for ongoing trials in the five major clinical trials registries.

纳入排除标准

Randomised controlled trials of danazol versus placebo or any other medical therapy in women with uterine fibroids confirmed by medical procedures, regardless of the women's symptoms or age. Studies of women with malignancies were excluded.

资料收集与分析

Data extraction and risk of bias assessment were not performed because there were no identified studies.

主要结果

We did not identify any studies which met our full inclusion criteria.

作者结论

There is no reliable evidence available from randomised controlled trials regarding the benefits or harms of the use of danazol for treating uterine fibroids.

引用文献
Ke L-q-, Yang K, Li C-M, Li J. Danazol for uterine fibroids. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007692. DOI: 10.1002/14651858.CD007692.pub2.

我们的Cookie使用

我们使用必要的cookie来使我们的网站工作。我们还希望设置可选的分析cookie,以帮助我们进行改进。除非您启用它们,否则我们不会设置可选的cookie。使用此工具将在您的设备上设置一个cookie来记住您的偏好。您随时可以随时通过单击每个页面页脚中的“Cookies设置”链接来更改您的Cookie首选项。
有关我们使用cookie的更多详细信息,请参阅我们的Cookies页面

接受全部
配置